Summit Therapeutics (SMMT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $13.06B and a free-cash-flow yield of -2.6%. Nama's AI scorecard rates it Sell, 3.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.
AI scorecard
Sell · 3.2/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Momentum
Lagging · -2.7% over 12 months ex. last
Second-worst fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-55.8%
How far the last close sits under the highest price of the past five years.
Market cap
$13.06B
Trailing P/E
—
Price / book
20.7
Price / sales
—
FCF yield
-2.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
-100.0%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
-1.5
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
SMMT earnings
Next report: Feb 22, 2027 (Q4 2026, EPS estimate -$0.26).
Beat the EPS estimate in 2 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 4, 2026
-$0.19
-$0.21
+9.5%
$0
Q2 2026
Jul 23, 2026
-$0.21
-$0.21
+0.0%
$0
Q1 2026
Apr 30, 2026
-$0.18
-$0.21
+14.3%
$0
Q4 2025
Feb 23, 2026
-$0.21
-$0.01
-2000.0%
$0
SMMT analyst price target
Median target $33.12 from 13 analysts, ranging $11.88 – $43.67.
Nama's AI scorecard currently rates Summit Therapeutics Sell (3.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SMMT report earnings?
Summit Therapeutics's next scheduled report is on Feb 22, 2027. Analysts expect EPS of -$0.26.
What is the SMMT price target?
The median analyst price target from 13 analysts is $33.12, with a range of $11.88 – $43.67.
Is SMMT Shariah compliant?
Nama's AAOIFI-style screen reads Summit Therapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.